FDA Grants Breakthrough Designation to Urine-Based Multi-Cancer Test

What Happened

The U.S. Food and Drug Administration has granted Breakthrough Device Designation to TOBY Inc. for its urine-based multi-cancer early detection (MCED) test, the company announced. The designation is reserved for medical devices that provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions compared to currently available alternatives.

What the Designation Means

The FDA's Breakthrough Device Designation is a formal regulatory pathway, not a product approval. It entitles TOBY Inc. to more intensive guidance from the FDA during the device's development and review process, with the goal of expediting access to patients. The designation does not confirm that the test is safe or effective, nor does it guarantee ultimate approval. To qualify, a device must demonstrate the potential to provide more effective diagnosis or treatment of a serious condition, and must use a technology that is novel or offers advantages over existing options.

For TOBY Inc., the designation applies specifically to a test that uses urine as its biological sample source, rather than blood draws, tissue biopsies, or other more invasive collection methods. The test is designed to detect signals associated with multiple cancer types from a single sample.

Background on Multi-Cancer Early Detection

Multi-cancer early detection tests have attracted significant investment and regulatory attention in recent years. The general category aims to identify cancer-associated markers, such as circulating tumor DNA or proteins, in biological fluids before symptoms appear. Most tests currently in development or approved use blood samples. A urine-based approach would represent a less invasive collection method, which developers in the field have argued could improve patient participation rates in screening programs.

Several companies are competing in the MCED space. Grail, a subsidiary of Illumina, received FDA approval for its Galleri blood-based MCED test in 2024. Other companies, including Exact Sciences and Guardant Health, have active programs targeting multi-cancer detection. TOBY Inc.'s urine-based approach positions it differently from the majority of blood-based competitors currently in the market or under review.

What the Test Does

According to the announcement, TOBY Inc.'s test analyzes urine samples to detect biomarkers associated with multiple cancer types at early stages. The company has not publicly disclosed in available reports which specific cancer types the test is designed to identify, nor the number of cancer types covered by the current version of the test. Sensitivity and specificity data from clinical studies were not included in the available wire report details.

Urine-based liquid biopsy technology has been an active area of research, with urine shown to contain shed cancer-associated DNA, proteins, and exosomes that can, under certain conditions, provide diagnostic signals for cancers of the urinary tract and, in some studies, cancers beyond that system.

Company Profile

TOBY Inc. is a medical diagnostics company focused on non-invasive cancer detection. Further details on the company's funding status, clinical trial enrollment, or commercial timeline were not available in the wire reports reviewed for this article.

Regulatory Next Steps

With Breakthrough Device Designation confirmed, TOBY Inc. is expected to enter an interactive review process with the FDA, during which the agency will provide guidance on the clinical evidence required to support a future submission for market authorization.